Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease.
Identifieur interne : 002B76 ( Main/Exploration ); précédent : 002B75; suivant : 002B77Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease.
Auteurs : Simon Lemay [Canada] ; Sylvain Chouinard ; Pierre Blanchet ; Hélène Masson ; Valérie Soland ; Anne Beuter ; Marc-André BédardSource :
- Progress in neuro-psychopharmacology & biological psychiatry [ 0278-5846 ] ; 2004.
English descriptors
- KwdEn :
- Administration, Cutaneous, Aged, Biomechanical Phenomena, Cognition Disorders (drug therapy), Cognition Disorders (etiology), Female, Humans, Male, Middle Aged, Movement Disorders (drug therapy), Movement Disorders (etiology), Neuropsychological Tests, Nicotine (administration & dosage), Nicotine (blood), Nicotine (therapeutic use), Nicotinic Agonists (administration & dosage), Nicotinic Agonists (blood), Nicotinic Agonists (therapeutic use), Parkinson Disease (complications), Parkinson Disease (drug therapy), Psychomotor Performance (drug effects), Reaction Time (drug effects), Verbal Learning (drug effects).
- MESH :
- chemical , administration & dosage : Nicotine, Nicotinic Agonists.
- chemical , blood : Nicotine, Nicotinic Agonists.
- complications : Parkinson Disease.
- drug effects : Psychomotor Performance, Reaction Time, Verbal Learning.
- drug therapy : Cognition Disorders, Movement Disorders, Parkinson Disease.
- etiology : Cognition Disorders, Movement Disorders.
- chemical , therapeutic use : Nicotine, Nicotinic Agonists.
- Administration, Cutaneous, Aged, Biomechanical Phenomena, Female, Humans, Male, Middle Aged, Neuropsychological Tests.
Abstract
Studies assessing the efficacy of nicotine in Parkinson's disease (PD) have generated contradictory results. The controversy seems to stem from uncontrolled factors including the lack of objective measures, the practice effect in a test-retest design, and the absence of plasmatic dosage. This study aimed at further controlling these factors using transdermal nicotine in PD.
DOI: 10.1016/S0278-5846(03)00172-6
PubMed: 14687854
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001391
- to stream PubMed, to step Curation: 001391
- to stream PubMed, to step Checkpoint: 001391
- to stream Ncbi, to step Merge: 000381
- to stream Ncbi, to step Curation: 000381
- to stream Ncbi, to step Checkpoint: 000381
- to stream Main, to step Merge: 002F30
- to stream Main, to step Curation: 002B76
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease.</title><author><name sortKey="Lemay, Simon" sort="Lemay, Simon" uniqKey="Lemay S" first="Simon" last="Lemay">Simon Lemay</name><affiliation wicri:level="4"><nlm:affiliation>Cognitive Neuroscience Centre, Université du Québec à Montréal, Montreal, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Cognitive Neuroscience Centre, Université du Québec à Montréal, Montreal, Québec</wicri:regionArea><orgName type="university">Université du Québec à Montréal</orgName><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation></author><author><name sortKey="Chouinard, Sylvain" sort="Chouinard, Sylvain" uniqKey="Chouinard S" first="Sylvain" last="Chouinard">Sylvain Chouinard</name></author><author><name sortKey="Blanchet, Pierre" sort="Blanchet, Pierre" uniqKey="Blanchet P" first="Pierre" last="Blanchet">Pierre Blanchet</name></author><author><name sortKey="Masson, Helene" sort="Masson, Helene" uniqKey="Masson H" first="Hélène" last="Masson">Hélène Masson</name></author><author><name sortKey="Soland, Valerie" sort="Soland, Valerie" uniqKey="Soland V" first="Valérie" last="Soland">Valérie Soland</name></author><author><name sortKey="Beuter, Anne" sort="Beuter, Anne" uniqKey="Beuter A" first="Anne" last="Beuter">Anne Beuter</name></author><author><name sortKey="Bedard, Marc Andre" sort="Bedard, Marc Andre" uniqKey="Bedard M" first="Marc-André" last="Bédard">Marc-André Bédard</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:14687854</idno><idno type="pmid">14687854</idno><idno type="doi">10.1016/S0278-5846(03)00172-6</idno><idno type="wicri:Area/PubMed/Corpus">001391</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001391</idno><idno type="wicri:Area/PubMed/Curation">001391</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001391</idno><idno type="wicri:Area/PubMed/Checkpoint">001391</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001391</idno><idno type="wicri:Area/Ncbi/Merge">000381</idno><idno type="wicri:Area/Ncbi/Curation">000381</idno><idno type="wicri:Area/Ncbi/Checkpoint">000381</idno><idno type="wicri:doubleKey">0278-5846:2004:Lemay S:lack:of:efficacy</idno><idno type="wicri:Area/Main/Merge">002F30</idno><idno type="wicri:Area/Main/Curation">002B76</idno><idno type="wicri:Area/Main/Exploration">002B76</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease.</title><author><name sortKey="Lemay, Simon" sort="Lemay, Simon" uniqKey="Lemay S" first="Simon" last="Lemay">Simon Lemay</name><affiliation wicri:level="4"><nlm:affiliation>Cognitive Neuroscience Centre, Université du Québec à Montréal, Montreal, Québec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Cognitive Neuroscience Centre, Université du Québec à Montréal, Montreal, Québec</wicri:regionArea><orgName type="university">Université du Québec à Montréal</orgName><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation></author><author><name sortKey="Chouinard, Sylvain" sort="Chouinard, Sylvain" uniqKey="Chouinard S" first="Sylvain" last="Chouinard">Sylvain Chouinard</name></author><author><name sortKey="Blanchet, Pierre" sort="Blanchet, Pierre" uniqKey="Blanchet P" first="Pierre" last="Blanchet">Pierre Blanchet</name></author><author><name sortKey="Masson, Helene" sort="Masson, Helene" uniqKey="Masson H" first="Hélène" last="Masson">Hélène Masson</name></author><author><name sortKey="Soland, Valerie" sort="Soland, Valerie" uniqKey="Soland V" first="Valérie" last="Soland">Valérie Soland</name></author><author><name sortKey="Beuter, Anne" sort="Beuter, Anne" uniqKey="Beuter A" first="Anne" last="Beuter">Anne Beuter</name></author><author><name sortKey="Bedard, Marc Andre" sort="Bedard, Marc Andre" uniqKey="Bedard M" first="Marc-André" last="Bédard">Marc-André Bédard</name></author></analytic><series><title level="j">Progress in neuro-psychopharmacology & biological psychiatry</title><idno type="ISSN">0278-5846</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Cutaneous</term><term>Aged</term><term>Biomechanical Phenomena</term><term>Cognition Disorders (drug therapy)</term><term>Cognition Disorders (etiology)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Movement Disorders (drug therapy)</term><term>Movement Disorders (etiology)</term><term>Neuropsychological Tests</term><term>Nicotine (administration & dosage)</term><term>Nicotine (blood)</term><term>Nicotine (therapeutic use)</term><term>Nicotinic Agonists (administration & dosage)</term><term>Nicotinic Agonists (blood)</term><term>Nicotinic Agonists (therapeutic use)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Psychomotor Performance (drug effects)</term><term>Reaction Time (drug effects)</term><term>Verbal Learning (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Nicotine</term><term>Nicotinic Agonists</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Nicotine</term><term>Nicotinic Agonists</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Psychomotor Performance</term><term>Reaction Time</term><term>Verbal Learning</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Cognition Disorders</term><term>Movement Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cognition Disorders</term><term>Movement Disorders</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Nicotine</term><term>Nicotinic Agonists</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Cutaneous</term><term>Aged</term><term>Biomechanical Phenomena</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neuropsychological Tests</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Studies assessing the efficacy of nicotine in Parkinson's disease (PD) have generated contradictory results. The controversy seems to stem from uncontrolled factors including the lack of objective measures, the practice effect in a test-retest design, and the absence of plasmatic dosage. This study aimed at further controlling these factors using transdermal nicotine in PD.</div></front></TEI><affiliations><list><country><li>Canada</li></country><region><li>Québec</li></region><settlement><li>Montréal</li></settlement><orgName><li>Université du Québec à Montréal</li></orgName></list><tree><noCountry><name sortKey="Bedard, Marc Andre" sort="Bedard, Marc Andre" uniqKey="Bedard M" first="Marc-André" last="Bédard">Marc-André Bédard</name><name sortKey="Beuter, Anne" sort="Beuter, Anne" uniqKey="Beuter A" first="Anne" last="Beuter">Anne Beuter</name><name sortKey="Blanchet, Pierre" sort="Blanchet, Pierre" uniqKey="Blanchet P" first="Pierre" last="Blanchet">Pierre Blanchet</name><name sortKey="Chouinard, Sylvain" sort="Chouinard, Sylvain" uniqKey="Chouinard S" first="Sylvain" last="Chouinard">Sylvain Chouinard</name><name sortKey="Masson, Helene" sort="Masson, Helene" uniqKey="Masson H" first="Hélène" last="Masson">Hélène Masson</name><name sortKey="Soland, Valerie" sort="Soland, Valerie" uniqKey="Soland V" first="Valérie" last="Soland">Valérie Soland</name></noCountry><country name="Canada"><region name="Québec"><name sortKey="Lemay, Simon" sort="Lemay, Simon" uniqKey="Lemay S" first="Simon" last="Lemay">Simon Lemay</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B76 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002B76 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:14687854
|texte= Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:14687854" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |